Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
it was big volume all at about $4 the other day... such big volume it obscures whatever happened on the previous months spikes.
vol by price is the horizontal black and red bars on this chart. shows the force and strength at certain price points based on previous trading through those levels. 3 year chart shows how big that volume really was compared to the last 3 years.
whole outstanding float 26million at the time volume in three days was like 55million shares!!!
i think there is a month or two where 2.35 could be tested a few times.
at the time, that february spike was pretty big volume, and I don't remember if I was watching the tape that day but I think it was sparked by a record volume day on the austrailian index right around when a paper was published but slowly circulated without much pr.
WTF! who are the dumbasses that made the gap up??? you all had plenty of time to buy with stealth! ;^)
The PR doesn't say the PET scans would exclusively be funded by this award.
pressure blowing... this is sick... wonder if shareholder meeting will be pred around time of april 13.
healing holes in the head.
CRIS: were there any pictures from AACR?
PBTH BTX TRGT ONCY
I hadn't seen this seeking alpha thing.
Authors:
4 Biotech Companies With a 2-Year Cash Cushion, Being Snapped Up by the Smart Money 5 comments | by: Kapitall March 28, 2011 | about: BTX, ONCY, PBTH, TRGT Font Size: PrintEmail Recommend 1 Share this page
Share0 Here we present 4 biotech companies that are “cash-comfortable”, with enough cash to cover more than 8 quarters of their average quarterly operating expenses. These four stocks are also seeing net buying from both institutional and mutual fund holders over the current and prior quarters.
For these companies we calculated the average quarterly operating expense over the last four quarters, and compared it with current cash holdings. All four companies listed have more than 8x the cash for their avg. quarterly operating expense, translating into coverage of more than 8 quarters of avg. operating expenses without the need to generate revenue.
Do you think these names can continue to attract institutional flows? We included full sentiment analyses, a recap of recent developments for the companies, as well as the data we mentioned above.
Cash and operating expense data sourced from Google Finance, institutional and mutual fund data sourced from Fidelity.
List sorted by current cash holdings divided by avg. quarterly operating expense.
1. Targacept, Inc. (TRGT): Biotechnology Industry. Market cap of $723.76M. Net institutional shares bought during current quarter at 4.6M vs. 140.6K net shares bought during previous quarter. Net mutual fund shares bought during current quarter at 531.2K vs. 527.0K net shares bought during the previous quarter.
Current cash holdings at $252.51M vs. average quarterly operating expenses over the last four quarters at $18.15M. Cash/Avg. Quarterly Operating Expenses at 13.9, i.e. the company can go 13.9 quarters without generating revenue and still cover the average quarterly operating costs.
Recent developments: Announced results from a Phase II trial of TC-5619 for treating adults with ADHD, finding it did not meet its primary efficacy outcome measure (Mar. 2011); however, TC-5619 gave positive results from a separate Phase II trial for cognitive dysfunction in schizophrenia (Jan. 2011). Announced FY11 revenue guidance below analysts’ estimates (Feb. 2011).
2. PROLOR Biotech, Inc. (PBTH): Biotechnology Industry. Market cap of $320.44M. Net institutional shares bought during current quarter at 1.4M vs. 333.5K net shares bought during previous quarter. Net mutual fund shares bought during current quarter at 1.1M vs. 33.0K net shares bought during the previous quarter.
Current cash holdings at $25.91M vs. average quarterly operating expenses over the last four quarters at $1.92M. Cash/Avg. Quarterly Operating Expenses at 13.5, i.e. the company can go 13.5 quarters without generating revenue and still cover the average quarterly operating costs.
Recent developments: Announced positive pre-clinical results from a comparative study of its longer-acting version of hemophilia drug Factor IX (Feb. 2011).
3. BioTime, Inc. Common Stock (BTX): Biotechnology Industry. Market cap of $359.80M. Net institutional shares bought during current quarter at 920.5K vs. 1.4M net shares bought during previous quarter. Net mutual fund shares bought during current quarter at 202.3K vs. 243.5K net shares bought during the previous quarter.
Current cash holdings at $33.32M vs. average quarterly operating expenses over the last four quarters at $3.38M. Cash/Avg. Quarterly Operating Expenses at 9.9, i.e. the company can go 9.9 quarters without generating revenue and still cover the average quarterly operating costs.
Recent developments: Announced closing of merger of Glycosan BioSystems, Inc. with wholly-owned subsidiary OrthoCyte Corp. (Mar. 2011). Announced the company had acquired all assets of Cell Targeting, Inc., whose technology uses peptides that can adhere to diseased tissues to potentially revolutionize cell therapy.
4. Oncolytics Biotech Inc. (ONCY): Biotechnology Industry. Market cap of $409.0M. Net institutional shares bought during current quarter at 8.1M vs. 713.9K net shares bought during previous quarter. Net mutual fund shares bought during current quarter at 16.5K vs. 39.6K net shares bought during the previous quarter.
Current cash holdings at $42.91M vs. average quarterly operating expenses over the last four quarters at $5.01M. Cash/Avg. Quarterly Operating Expenses at 8.6, i.e. the company can go 8.6 quarters without generating revenue and still cover the average quarterly operating costs.
Recent developments: Announced positive results for the first part of its Phase II trial for treating advanced pancreatic cancer with intravenous REOLYSIN in combination with gemcitabine (Feb. 2011). Announced opening of enrollment for the company’s Phase I trial of REOLYSIN with FOLFIRI for treating colorectal cancer (Jan. 2011).
http://seekingalpha.com/article/260439-4-biotech-companies-with-a-2-year-cash-cushion-being-snapped-up-by-the-smart-money?source=yahoo
Bustin' a nut.
Pran getting another $700,000 from ADDF and announces plans for small phase II trial to get lots of PET scan pictures of brains and amyloid neroimaging on drug and not on drug, they want pictures of "target engagement" and want to see metals move around and cognitive improvements. I don't think they care at all about plaque reduction.
I feel sorry for the patients that showed cognitive improvement on the short trial...
Prana's PBT2 Phase II Trial Receives Funding From Alzheimer's Drug Discovery Foundation
Funding Provided to Demonstrate Benefits of PBT2 in a 12 Month Brain Imaging Trial
Press Release Source: Prana Bitoechnology On Thursday March 31, 2011, 9:40 am
MELBOURNE, AUSTRALIA--(Marketwire - 03/31/11) - The New York based Alzheimer's Drug Discovery Foundation (ADDF) and Prana Biotechnology (NASDAQ:PRAN - News) (ASX:PBT - News) today jointly announced that the ADDF will provide Prana with a mission-related investment of US$700,000 over two years to conduct a clinical trial investigating the potential of PBT2 to reduce the accumulation of beta-amyloid in the brain of people with Alzheimer's Disease (AD). Beta-amyloid is thought to be a cause of brain cell death and dementia in Alzheimer's Disease. The Phase II study will enroll 40 patients with mild AD for 12 months, with Positron Emission Tomography (PET) amyloid neuroimaging and other biomarkers as the primary outcome measures.
Howard Fillit, MD, the ADDF's Executive Director commented that "PBT2 stands out as one of the few orally available agents with clinical trial evidence of cognitive benefit for Alzheimer's patients. If this Phase II trial is successful, it will further demonstrate target engagement by PBT2 in the brain of people with Alzheimer's Disease. It is hoped that these additional data will accelerate the clinical development of PBT2 to patients."
Previously PBT2 demonstrated a significant decrease in beta-amyloid in the cerebrospinal fluid and significantly improved executive function in mild Alzheimer's Disease patients within three months of treatment*. The ADDF funded Phase II study will ask the question, 'what is happening to the amyloid burden of these patients using the same dose that previously resulted in cognitive improvements, and is this change sustainable?' Since the number of patients in the study is relatively small, cognitive function will be included as a secondary outcome measure.
"We are honored to be selected for funding by the ADDF, an organization that is internationally recognized as supporting some of the most ground breaking drug discovery and development research today in Alzheimer's Disease," said Mr. Geoffrey Kempler, Prana's Executive Chairman. "The trial will advance our understanding of PBT2's potential mechanism of action for disease modification in humans, a critical step forward that complements our strategic plan to advance PBT2 through clinical trials for the treatment of both Alzheimer's and Huntington's Disease."
The Phase II trial is planned to commence in Australia in the second half of 2011. It will recruit patients with mild Alzheimer's Disease who have demonstrated evidence of amyloid burden in the brain by PET-amyloid imaging.
*Lannfelt et al. Lancet Neurology (2008) vol. 7, pp. 779-86; Lannfelt et al. Lancet
Neurology (2009) vol. 8, pp. 981.
About the Alzheimer's Drug Discovery Foundation (ADDF)
The ADDF (www.alzdiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's Disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 17 countries.
For more information about the ADDF or to speak with Dr. Fillit, please contact Filomena Machleder at 212-901-8004 begin_of_the_skype_highlighting 212-901-8004 end_of_the_skype_highlighting or fmachleder@alzdiscovery.org.
About Prana Biotechnology
Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.
For further information please visit the Company's web site at www.pranabio.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.
Contact:
Contacts:Prana Biotechnology Limited+61 3 9349 4906 begin_of_the_skype_highlighting +61 3 9349 4906 end_of_the_skype_highlightingInvestor RelationsLeslie Wolf-CreutzfeldtGrayling646-284-9472 begin_of_the_skype_highlighting 646-284-9472 end_of_the_skype_highlighting
Wow you guys are chatty. One blue line after another they eventually get punctured and the price goes higher. They just needed a little bit more money for a big trial. The Austrailian money was good for about a year at the burn rate of a company that would be about to do a big phase III $12M or so.
Also note that there is a hunger for neuro- drugs despite what was reported the other day.
LMAO!!! $1480 by the end of the week.
you like aen why follow coatails of pran?
just kidding, but aen has more upward slant to chart and pran looks like recent breakout.
aen to 6 pran to 10?
Nice follow through today so far.
PRAN finally got through resistance at $1.63ish.
what is wrong with gold trading... is it just the finviz website? seems stuck right after 6pm
http://finviz.com/futures_charts.ashx?t=GC&p=m5
AMLN... once a month formulation gives 1.3-1.5% average A1C reduction.
That seems like a big deal.
AMLN must be pulling their hair out focusing on that 1.5% number for Victoza.
This had a Bydureon arm and they are quick to point out that they hit 1.5% there too.
Dpdw...Ka-ching!
$100 day for gold soon.
very nicely recovered and follow through today.
Officially, nothing, according to the company.
Only thing they offer as an explaination is the an online report that I haven't seen.
http://www.asx.com.au/asxpdf/20110218/pdf/41ww10m2g9r1mq.pdf
thanks I won't be able to dig the rest of the day.
Any idea why PRAN is running?
I haven't seen. just know australian exchange ran up on no news and us is following with monster volume... all i can figure.
definetely smells like a leak or it could be that the chart was about to fail and it turned.
PRAN.
the day you posted here was 4/20 ha ha ha.
still a good stock as long as it's under $5 by april.
Apr 22, 2010 1.75 1.88 1.67 1.72 573,300 1.72
Apr 21, 2010 1.91 1.96 1.72 1.75 752,600 1.75
Apr 20, 2010 2.24 2.30 1.86 1.91 2,567,100 1.91
Apr 19, 2010 1.37 3.35 1.35 2.41 7,522,300 2.41
Apr 16, 2010 1.36 1.39 1.31 1.35 10,400 1.35
PRAN
AYSI is a tiny company that is in a sweet spot in the mining industry. I think they are in a position to be bought by cat or deere.
The CEO and original inventor is steping to the side to be a technical director and executives from a 4-5 month search will be announced soon.
Gene grew the company almost always using organic growth and no equity.
Interesting links below.
One thing I remember Gene saying they were interested in spending some money on nanotech, I think he has another invention in mind. The way they make the plates is pretty much harnessing lightning. There are plenty of cool pics on their website.
http://www.alloysteel.net/media/pdf/aysi-chairmans-letter-and-2010-accounts.pdf
http://www.alloysteel.net/corporate-profile.html?PHPSESSID=b31836351f2eb1693e887e9f9cb3d8a2
http://www.alloysteel.net/media/pdf/aysi-director-search.pdf
pics in these links:
sluice boxes and fixed applications:
http://www.alloysteel.net/media/pdf/fixed-plant-applications-brochure.pdf
mobile stuff:
http://www.alloysteel.net/media/pdf/mobile-plant-applications-brochure.pdf
pictures during manufacture:
http://www.alloysteel.net/media/pdf/arcoplate-white-brochure.pdf
AYSI: I have had AYSI for a long time and I guess it's a good general stock idea.
Picks and shovels play on the global mining boom.
They use "lightning" to make super thick plates of alloy steel to line buckets and shovels of mining equipment.
BHP Billition is a major customer and partner. The old man inventor Gene is stepping down as CEO and it was revealed on the AYSI website.
Investors are watching the land aquisition and understand that there is more than enough space in that new facility... about 8x as large as the original mills, so maybe they could put two new mills there and have room to assemble large orders.
http://www.alloysteel.net/
http://www.alloysteel.net/corporate-profile.html?PHPSESSID=b31836351f2eb1693e887e9f9cb3d8a2
http://www.alloysteel.net/media/pdf/aysi-chairmans-letter-and-2010-accounts.pdf
your time is up for the contest. feel free to make another prediction and add it to the following list of predictions:
"one hundred dollar day contest"
guess a date for the first $100 intraday swing in gold prices... closest without going over wins the title of "winner".
gym gravity: april 1 2011
Gold going nuts. I'll keep reading.
I spent time in a few jewelry stores on Sunday in Chinatown (new year celebration, lion dances, firecrackers. I handled some large chinese 24k bracelets but not heavy bullion bracelets. I tried to buy a bullion bracelet from bullion jewelry.com but they are no longer in buisiness. I called them and emailed them.
\by the way when do you think the first $100 day will come?
RBCN has good news:
premarket bid ask:
Bid: 25.10 x 500
Ask: 26.49 x 100